The PPARgamma-selective ligand rosiglitazone differentially regulates the fate of choice of dental pulp mesenchymal stem cells versus bone marrow mesenchymal stem cells

• Main Authors: Hung-Chang Lai, 賴泓璋
• Other Authors: Shou-Yen Kao
• Format: Others
• Language: en_US
• Published: 2009
• Online Access: http://ndltd.ncl.edu.tw/handle/64936094093287562347

碩士 === 國立陽明大學 === 臨床牙醫學研究所 === 97 === Tissue engineering with stem cells will be the future trend of medical treatment, and the source of stem cells can be isolated from different tissue of human body. Now we present the mesenchymal stem cells (MSCs) from dental pulp which is a luxury source of stem cells and we compared the property between dental pulp mesenchymal stem cells (DPSCs) and bone marrow mesenchymal stem cells (BMSCs). Osteoblasts and adipocytes are derived from a common mesenchymal progenitor and an inverse relationship between expressions of the two lineages is seen with certain experimental manipulations and in certain diseases, i.e., osteoporosis, but the cellular pathway and development stage underlying the inverse relationship is still under active investigation. To determine which precursor mesenchymal cell types can differentiate into adipocytes, we compared the effects of Rosiglitazone(Rosi) a selective ligand for peroxisome proliferators-activated receptor (PPAR) γ, a master transcription factor of adipogenesis, on osteo/adipogeneis in two different osteoblast culture models: human dental pulp stem cells and bone marrow stem cells.Under osteo/adipogenesis differentiation, we found that dental pulp stem cells have better osteogenetic ability but poor adipogenetic ability versus bone marrow stem cells. Rosi increased the number of adipocytes and corresponding marker expression in BMSCs culture models, and also affected osteoblastogenesis only inBMSCs, but not in DPSCs.The data show that there are clear differences in differention potential between DPSCs and BMSCs. The Rosi has the ability of changing the fate of BMSCs than in DPSCs.